Liu Tianyu, Schwartz Turner, Chebolu Apoorv P, Tsui Jonathan C, Bhatt Nirali, Scoles Drew
Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania; and.
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Retin Cases Brief Rep. 2024 Sep 1;18(5):580-584. doi: 10.1097/ICB.0000000000001449.
To report a case of presumed teclistamab-associated sclerouveitis with hypopyon.
Case report.
A 62-year-old woman with relapsed refractory multiple myeloma presented with right eye pain and decreased vision 1 week after starting teclistamab and was found to have sclerouveitis with hypopyon. She received intravitreal vancomycin and ceftazidime because of the concern for infectious endophthalmitis, but cultures were negative. Systemic workup for infectious and inflammatory etiologies was unremarkable. Her signs and symptoms improved with topical steroids and a 1-week pause in teclistamab. This case constituted a Naranjo Adverse Drug Reaction Probability Scale score of 5, representing a "probable" association.
Teclistamab, a novel bispecific antibody recently approved for the treatment of relapsed or refractory multiple myeloma, may be associated with sclerouveitis with hypopyon.
报告一例疑似与替西妥单抗相关的伴有前房积脓的巩膜葡萄膜炎病例。
病例报告。
一名62岁复发难治性多发性骨髓瘤女性患者，在开始使用替西妥单抗1周后出现右眼疼痛和视力下降，被发现患有伴有前房积脓的巩膜葡萄膜炎。由于担心感染性眼内炎，她接受了玻璃体内注射万古霉素和头孢他啶，但培养结果为阴性。针对感染性和炎性病因的全身检查无异常。她的体征和症状通过局部使用类固醇以及暂停使用替西妥单抗1周后有所改善。该病例的Naranjo药物不良反应概率量表评分为5分，表明为“很可能”的关联。
替西妥单抗是一种最近被批准用于治疗复发或难治性多发性骨髓瘤的新型双特异性抗体，可能与伴有前房积脓的巩膜葡萄膜炎有关。
